Unlock instant, AI-driven research and patent intelligence for your innovation.

Treatment of bladder cancer by local administration of taxane particles

A taxane and bladder cancer technology, applied in medical preparations with non-active ingredients, medical preparations containing active ingredients, drug combinations, etc., can solve problems such as inability to obtain survival rates

Pending Publication Date: 2020-09-04
CRITITECH INC
View PDF18 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite providing good local control, surgery alone does not yield optimal survival

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of bladder cancer by local administration of taxane particles
  • Treatment of bladder cancer by local administration of taxane particles
  • Treatment of bladder cancer by local administration of taxane particles

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0295] The preparation of embodiment 1 paclitaxel granules and docetaxel granules

[0296] Materials and methods

[0297] Raw material paclitaxel and docetaxel were purchased from Phyton Biotech (British Columbia, Canada) with lot numbers FP2-15004 and DT7-14025, respectively. Both are in their original form. Milling of both drugs was done using a Deco-PBM-V-0.41 mill (Deco). The milling conditions for the two compounds were as follows:

[0298] Ball diameter = 5mm;

[0299] RPM = 600;

[0300] Processing time = 60min;

[0301] room temperature.

[0302] Preparation of Paclitaxel Granules

[0303] A 65 mg / ml solution of paclitaxel was prepared in acetone. Will BETE The spray nozzle (produced by BETE FogNozzle, Inc) and the acoustic wave probe (Qsonica, model number Q700) were placed in the crystallization chamber with a distance of about 8 mm. A stainless steel mesh filter with pores of about 100 nm was installed on the crystallization chamber to collect the precipi...

Embodiment 2

[0337] Example 2. Pilot Evaluation Study of Direct Injection of Dye into Rabbit Bladder Wall

[0338] A study was performed to evaluate the injection of blue tissue dye in a vehicle formulation directly into the bladder wall of rabbits (intratumoral injection). Injection into the bladder wall is the administration of nDoce (docetaxel nanoparticles as disclosed herein, the purity of the docetaxel used in this example is about 99%, the average particle size (number) is 1.078 μm, and the SSA is 37.2 μm in the human body. 2 / g, the bulk density (uncompacted) is 0.0723g / cm 3 ) expected route of the suspension. Due to the similarity in bladder wall musculature and bladder size, rabbits are a suitable species for research. The vehicle formulation contained 0.4% w / w polysorbate 80NF, 3.2% w / w ethanol (200 proof), prepared in sterile saline solution (0.9% sodium chloride injection, USP). Add 10 mg / ml Evans blue tissue dye to the vehicle, which is sufficient for visualization.

[03...

Embodiment 3

[0341] Example 3. nDoce single-dose intratumoral toxicity ranging and toxicokinetic study in mice

[0342] Non-GLP studies were performed to evaluate and characterize the experimental sample nDoce (docetaxel nanoparticles as disclosed herein, the purity of docetaxel used in this example was about 99%, the average particle size (number) was 1.078 μm, and the SSA was 37.2m 2 / g, the bulk density is 0.0723g / cm 3 ) toxicity and toxicokinetics, and intratumoral administration to [Contrast: (SD)] Retrovesical assessment of maximum tolerated dose (MTD) in female mice. The intratumoral route is the intended route of administration of nDoce suspension in humans. Mice are a commonly used rodent model for assessing the toxicity of various chemicals, and there are extensive historical databases. Female mice were chosen for this study considering the ease of urethral catheterization in female versus male mice. Animals were maintained in a post-dose recovery period of 72 hours or 14...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
The average particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
Specific surface areaaaaaaaaaaa
Login to View More

Abstract

Disclosed herein are methods for treating and inhibiting the recurrence of bladder cancer by local administration of compositions comprising taxane particles such as docetaxel particles. The administration methods include intratumoral injection, direct injection into surgical tumor resection sites, and intravesical instillation.

Description

[0001] cross reference [0002] This application enjoys the priority of a series of U.S. patent applications, including the application number 62 / 614064 submitted on January 5, 2018; the application number 62 / 779317 submitted on December 13, 2018; Application; Application No. 62 / 740489 submitted on 2018.10.3; Application No. 62 / 779327 submitted on 2018.12.13; Application No. 62 / 740501 submitted on 2018.10.3; Application No. 62 / 740501 submitted on 2018.12.13 779320 application. Each of the foregoing is hereby incorporated by reference in its entirety. technical field [0003] The present invention generally relates to the technical field of bladder cancer treatment. Background technique [0004] Bladder cancer is the most common cancer of the urinary system, accounting for approximately 5 percent of all new cancers in the United States. Bladder cancer is the sixth most common cancer in the United States, with an estimated 79,030 new cases and 6,870 deaths in 2017. Most bl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K9/10A61K9/14A61P35/00A61K31/337A61K47/26A61K9/16
CPCA61K47/26A61K9/16A61P35/00A61K9/0019A61K9/10A61K9/14A61K31/337Y02A50/30A61K9/0034A61K9/08
Inventor 盖尔·S·迪泽加迈克尔·巴尔特佐查尔斯·J·德塞杜山姆·坎贝尔马修·麦克洛雷
Owner CRITITECH INC